Poseida Therapeutics, Inc. (PSTX) Q3 Earnings and Revenues Beat Estimates
Portfolio Pulse from
Poseida Therapeutics, Inc. (PSTX) reported Q3 earnings of $0.21 per share, surpassing the Zacks Consensus Estimate of a loss of $0.42 per share. This marks a significant improvement from the loss of $0.35 per share a year ago.
November 08, 2024 | 12:15 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Poseida Therapeutics reported a positive Q3 earnings surprise with $0.21 per share, beating expectations of a $0.42 loss. This is a notable improvement from the previous year's loss.
The positive earnings surprise and significant improvement from the previous year's loss are likely to boost investor confidence and positively impact PSTX's stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100